 |
text only |
|
|||||||||||||||||||||||||||||
Professional Profile
Research Interests: -Metabolism and cancer -MicroRNA and cancer -Cancer metastasis -Therapeutic resistance -Targeted cancer therapy Honors and Academic Achievements: -Vincent F. Kilborn, Jr. Cancer Research Scholar, USA Mitchell Cancer Institute (2007-present). -Second Prize Winner, Alexander Y-M Wang Memorial Awards, SCBA Annual Scientific Symposium Oral Competition (2003). -Sowell-Huggins Scholar for Excellence in Cancer Research, The University of Texas M.D. Anderson Cancer Center and Health Sciences Center at Houston (2000). -Principal Investigator, U.S. Department of Defense Breast Cancer Research Program Fellowship (1997). -Research Award for Outstanding Young Scientist, Science and Technology Association of Sichuan Province, China (1991). Education: -Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center (2001-2006). -Ph.D., The University of Texas M.D. Anderson Cancer Center and Health Science Center at Houston, Texas (2000). -M.D., West China University of Medical Sciences, Chengdu, China (1985). Professional Appointments: -Member, USA Mitchell Cancer Institute (2007-present). -Graduate Faculty, USA Graduate School (2007-present). -Assistant Professor, USA Department of Cell Biology & Neuroscience (2007-present). -Assistant Professor (Research), The University of Texas MD Anderson Cancer Center (2006- 2007). Service: -Editorial Board, PLoS ONE -Editorial Board, International Journal of Cell Biology -Editorial Board, World Journal of Biological Chemistry -Scientific Reviewer, Department of Defense Breast Cancer Research Program (2009 - present) -Scientific Reviewer, NIH Tumor Cell Biology (TCB) Study Section, 2012 -Reviewer for Cancer Research, Oncogene, Molecular Cancer Therapeutics, Molecular Cancer Research, PlosOne, Breast Cancer Research, International Journal of Cell Biology, Chemotherapy, Molecular Carcinogenesis, British Journal of Cancer, and Molecular Oncology. Scientific Focus: Dr. Tan is an associate professor of Oncologic Sciences and Vincent F. Kilborn, Jr. Cancer Research Scholar at the Mitchell Cancer Institute. His laboratory focuses on the molecular mechanisms of tumor progression, metastasis, and therapeutic resistance of human breast cancer, melanoma, and other cancer types. Currently Dr. Tan’s lab is studying growth factor receptors, such as HER-2/ErbB2, and transcription factors, such as HSF1, in mediating cancer metabolism, signal transduction, apoptosis, metastasis, and resistance to therapeutic agents. Another emphasis of his study is on the deregulation of microRNA in cancer progression and therapeutic resistance. The ultimate goal of Dr. Tan’s research is to translate the knowledge acquired in the laboratory into future novel therapeutics. Selected Publications: Recent Publications: 1. Huang J, Townsend C, Dou D, Liu H, and Tan M. (2011) OMIT: A Domain-Specific Knowledge Base for MicroRNA Target Prediction. Pharm Res. 2011 Aug 31. [Epub ahead of print] 2. Zhao Y, Liu H, Liu Z, Ding Y, LeDoux SP, Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, Liu B, Fodstad O, Chen J, Wu Y, Price JE, and Tan M. (2011) Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism. Cancer Res 71: 4585-97. (Featured on the Homepage of Cancer Research; featured in Nature/SciBX: Science-Business exchange) 3. Liu H, Tekle C, Chen YW, Kristian A , Zhao YH, Zhou M, Liu ZX, Ding Y, Wang B, Mælandsmo GM, Nesland JM, Fodstad O, and Tan M. (2011) B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther 10:960-71. 4. Zhao YH, Liu H, Riker AI, Fodstad O, LeDoux SP, Wilson GL, and Tan M (2011) Emerging Metabolic Targets in Cancer Therapy. Front Biosci. 16:1844-60 5. Zhou M, Liu ZX, Zhao YH, Ding Y, Liu H, Xi Y, Xiong W, Li GY, Lu J, Fodstad O, Riker AI, and Tan M. (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1). J Biol Chem. 285: 21496-21507. 6. Zhou M, Zhao YH, Ding Y, Liu H, Liu ZX, Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, Ledoux SP, and Tan M. (2010) Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol. Mol Cancer 9:33. (Marked “Highly accessed” and ranked as “No.1 most accessed paper in the past 30 days” and “Top 10 most accessed paper in the past year” by the journal) 7. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu DH, Fodstad O, and Tan M. (2009) Upregulation of LDH-A by ErbB2 through HSF1 promotes breast cancer cell glycolysis and growth. Oncogene 42: 3689–3701. (Featured in USA news release and local news media) Significant Publications: 1. Tan M, Jing T, Lee S, Lan KH, Li P, Nagata Y, Liu J, Arlinghaus R, Hung MC, and Yu D. (2002) Direct phosphorylation on tyrosine-15 of p34Cdc2 by ErbB2 receptor tyrosine kinase inhibits p34Cdc2 activation. Molecular Cell 9: 993-1004. (Featured as the cover article) 2. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, and Yu D. (2004) PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-121. (Featured in the News or Commentaries: Nature, N Engl J Med, Cancer Cell, cited more than 700 times) 3. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell, 6(5):459-69, 2004. (Featured in the commentary of Cancer Cell) 4. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC. (1998) Overexpression of ErbB2 blocks Taxol induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Molecular Cell, 2:581-91. 5. Tan M, Yao J, and Yu D. (1997) Overexpression of the c-erbB-2/neu gene enhanced intrinsic metastatic potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57:1199-1205. Patents: -Yu D, Yao J, Lan KH, Tan M et al. Novel strategy for targeting therapeutics in breast cancer therapy. United States, IDR filed. Research Support: -The Vincent F. Kilborn, Jr. Cancer Research Foundation -The Norwegian Radium Legater Award Title: B7-H3 in Breast Cancer Drug Resistance and Metastasis Goals: Investigate the role of B7-H3 in regulating breast cancer drug resistance and progression Role: Principal Investigator - NIH/NCI 1R01CA140472-01A1 (3/1/2011 - 2/28/2016) Title: Glucose Metabolism and ErbB2/Her2-Mediated Cancer Progression Goals: Investigate the role of oncogene ErbB2/Her2 in regulating cancer metabolism and progression Role: Principal Investigator |
||||
Ming Tan, M.D., Ph.D.University of South Alabama - Mobile Alabama 36688-0002 Appointments: Medical, Surgical and Gynecologic Oncology: (251) 665-8000 Radiation Oncology: (251) 445-9615 Administration: (251) 460-6993 For questions or comments Contact Us Date last changed: December 21, 2011 11:16 AM http://www.southalabama.edu/mci/tan.html |
 |